DALLAS, March 01, 2019 (GLOBE NEWSWIRE) -- via
OTC PR WIRE -- Puration, Inc. (PURA) today
announced a jump in sales of its EVERx CBD Sports Water since the
company introduced its all new formula and packaging. The new
EVERx formula and packaging was introduced first in Denver at West
Coast Venture Group’s (WCVC) Illegal Burger
and an inventory reorder is already in process. EVERx CBD
Sports Water is currently debuting it’s all new formula and
packaging at the world-renowned Arnold Sports Festival
this week in Columbus, Ohio where EVERx launched for the first time
ever in 2017. PURA recently announced its first European
distributor and EVERx will be featured later this month at a CBD
food and beverage convention in Europe. In response to EVERx
orders received in December and January, the company set a 2019 sales goal of $5
million and the recent response to the all-new EVERx CBD Sports
Water formula and packaging is a strong indication that the company
can reach that goal.
Analyst Speculative Buy Recommendation
and $0.25 PPS Target with $0.35 Upside
Goldman Small Cap Research issued a research
update on Puration, Inc. (PURA) yesterday
recommending a 'speculative-buy' rating
with a target price-per-share of $0.25, with noted potential
upside to the $0.35 mark.
The 2019 Arnold Sports Festival and the world-renowned Arnold Classic bodybuilding championships, already the world’s largest multi-sport festival, will grow even larger in 2019 as the four-day health and fitness celebration presents a record 80 sports and events February 28-March 3, 2019 in Columbus, Ohio.
The Arnold Sports Festival attracts an estimated 200,000 sports and fitness fans to watch more than 22,000 athletes compete in 80 sports and events, including 16 Olympic events, at the Greater Columbus Convention Center in downtown Columbus, the Ohio Expo Center and various other Central Ohio venues.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration,
Inc.
Brian Shibley,
[email protected]
(800) 861-1350